Compare Inovio Pharmaceuticals Inc (INO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Regeneron Pharmaceuticals Inc trades at $680.5 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 789.4× Inovio Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | REGN | |
|---|---|---|
Market Cap | $89.27M | $70.47B |
Sector | Health | Health |
52-Week High | $2.87 | $812.27 |
52-Week Low | $1.05 | $545.46 |
Enterprise Value | $60.28M | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
